New Diabetes Strategy Combines a Drug Class, Fasting, and Early Risk Tests to Guard Heart, Kidneys and Liver
Researchers propose a three‑part approach for type 1 diabetes—SGLT‑2 inhibitor drugs, timed intermittent fasting, and early beta‑cell stress testing—to reduce heart, kidney and liver damage while managing ketoacidosis risk.
Precise Timing and Targeting in Heart Procedures Show Promise in New Trials
Recent studies suggest that careful timing of TAVI vs. PCI and exact LV lead placement, plus sham‑controlled AF ablation, may reduce complications and boost patient quality of life.

Metabolic Clues Spot High‑Risk Early Type 1 Diabetes, While Opioid Choice Affects GLP‑1 Drug Safety
New studies show that stimulated beta‑cell function tests, combined with age and autoantibody type, can pinpoint single‑autoantibody carriers at >50% risk of developing type 1 diabetes within two years, while oxycodone started alongside GLP‑1RA therapy in type 2 diabetes patients markedly increases short‑term severe constipation and bowel obstruction risk.




